Technology Networks recently spoke with Brad Margus, CEO at Cerevance, to find out how the company is addressing key drug development challenges. In this industry insight, Margus tells us more about the company’s drug development pipeline and their lead candidate CVN424, which is currently being developed to treat Parkinson’s disease. He also explains how Cerevance’s Nuclear Enriched Transcript Sort sequencing (NETSseq) platform is helping to discover promising targets that could be exploited therapeutically.